Nymox Announces Prostate Cancer Clinical Trial Will Complete Prospective 18 Month Post-Treatment Assessments
October 08, 2015 at 11:00 AM EDT
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that that participants in prostate cancer clinical trial NX03-0040 had ...
